### **CAMBRIDGE INTERNATIONAL EXAMINATIONS**

Cambridge International Advanced Subsidiary and Advanced Level

## MARK SCHEME for the March 2016 series

# 9700 BIOLOGY

9700/22

Paper 2 (AS Level Structured Questions), maximum raw mark 60

This mark scheme is published as an aid to teachers and candidates, to indicate the requirements of the examination. It shows the basis on which Examiners were instructed to award marks. It does not indicate the details of the discussions that took place at an Examiners' meeting before marking began, which would have considered the acceptability of alternative answers.

Mark schemes should be read in conjunction with the question paper and the Principal Examiner Report for Teachers.

Cambridge will not enter into discussions about these mark schemes.

Cambridge is publishing the mark schemes for the March 2016 series for most Cambridge IGCSE® and Cambridge International A and AS Level components.



Page 2	Mark Scheme	Syllabus	Paper
	Cambridge International AS/A Level – March 2016	9700	22

### Mark scheme abbreviations:

; separates marking points

I alternative answers for the same point

R reject

A accept (for answers correctly cued by the question or by extra guidance)

**AW** alternative wording (where responses vary more than usual)

<u>underline</u> actual word given must be used by candidate (grammatical variants

accepted)

max indicates the maximum number of marks that can be given

**ora** or reverse argument

**mp** marking point (with relevant number)

ecf error carried forward

I ignore

**AVP** alternative valid point (examples given as guidance)

Page 3	Mark Scheme	Syllabus	Paper
	Cambridge International AS/A Level – March 2016	9700	22

1 A sucrose;

B peptide; A amide

C cellulose;

**D** biuret; **A** (dilute) potassium/sodium, hydroxide (solution) and

(dilute) copper sulfate (solution)

R Millon's solution

E glycerol;

[5]

[Total: 5]

2 (a) magnification =  $\frac{\text{image length}}{\text{actual length}}$  /AW; A M = I/A or M = O/A

correct calculation or to 2 or 3 significant figures using the correct calculation

(x) 2778/2780/2800;; (for 25 mm) **A** ± 1 mm in measurement

one mark if correct measurement <u>stated</u> and divided by actual size but incorrect answer owing to, rounding up error/incorrect conversion factor

(25000/9.0);

[3]

(b) spherical/spheroid/AW;

(nuclear) envelope/two (nuclear) membranes/double membrane; (containing) nuclear pores;

(contains) chromatin/chromosomes; DNA and, proteins/histones;

contains, nucleolus/nucleoli

or

nucleolus is/nucleoli are, dark(er) staining/spherical/defined;

AVP; e.g. outer membrane continuous with RER heterochromatin and euchromatin contains nucleoplasm

[max 3]

[Total: 6]

Page 4	Mark Scheme	Syllabus	Paper
	Cambridge International AS/A Level – March 2016	9700	22

3 (a) (i) a gene codes for a protein/gene coding for EPO;

ref. transcription; A gene 'switched on'

A increase gene expression

mRNA (required) for, EPO/protein, synthesis

or

mRNA involved in translation;

[max 2]

(ii) vesicles move to, cell (surface)/plasma, membrane (via cytoskeleton);

(vesicles) fuse/merge, with cell (surface) membrane;

exocytosis (occurs);

(movement of vesicle/exocytosis) requires, energy/ATP;

A active (process)

**R** active transport

[max 2]

(b) (i) EPO, binds to/combines with/AW, receptors;

receptors, complementary to/specific shape for, EPO;

A EPO fits into receptors

cell signalling/EPO binding leads to (specific) responses within the (target) cells/AW;

I cells respond to EPO

 $\underline{\text{only}},$  target/bone marrow, cells, have receptors, for EPO/specific to EPO ;

ora

A binding triggers responses only within, target/bone marrow, cells

[max 3]

(ii) too large;

ref. to shape, cannot pass through;

(protein) is, hydrophilic/water soluble, <u>and</u> cannot cross hydrophobic core (of phospholipid bilayer)/AW;

no specific membrane transport protein;

[max 1]

(c) stem cell; A haematopoietic stem cell

treat as neutral adult/non-embryonic/multipotent/stromal

[max 1]

Page 5	Mark Scheme	Syllabus	Paper
	Cambridge International AS/A Level – March 2016	9700	22

(d) max 3 if all description (D) or all explanation (E)

**A** Hb for haemoglobin <u>and</u> Hb concentration for mean Hb concentration **A** g per kg/g kg<sup>-1</sup>, for g per kg body mass

constant

- **D** Hb concentration, remains constant/of 12.6 g kg<sup>-1</sup>, for first two weeks (of investigation)/up to start of injections;
- E idea of regulation;

e.g. sufficient oxygen so no requirement for increased EPO

increase then decrease description

- **D** (then) increase in Hb concentration (from week 2) for 5 weeks/AW, then decrease (for last three weeks/to week 10);
- D data quote/manipulated data, to support; e.g. increase from 12.6 g kg<sup>-1</sup> (week 2) to15.3 g kg<sup>-1</sup> (week 7) increases by 2.7 g kg<sup>-1</sup> (to week 7) decrease from 15.3 g kg<sup>-1</sup> (week 7) to 13.7 g kg<sup>-1</sup> (week 10) decreases by 1.6 g kg<sup>-1</sup> (to week 10)

increase explanation

**E** EPO increases production of red blood cells that contain Hb/AW;

decrease explanation

E red blood cells, short life span/die;

E cell signalling stops/(target/bone marrow) cells no longer stimulated/AW;
A EPO, degraded/AW

increase after injections stop

- D Hb concentration increases for 1 week after injections have finished;
- **E** *idea of*, time delay for red blood cell production to stop/time for immature red blood cells to mature and be released into blood stream;
- AVP; e.g. steady increase as time required for, mitosis/cell proliferation/differentiation into red blood cells/production of haemoglobin

contributory factor for increase may be, accumulation/increased concentration, of EPO with injections

[max 4]

(e) high altitudes and low oxygen partial pressure so less oxygen in inhaled air/less oxygen (would be) transported to tissue/AW;

lower oxygen saturation of haemoglobin/haemoglobin has lower oxygen affinity;

body requires more red blood cells that contain haemoglobin/AW;

A more red blood cells produced so more haemoglobin (to bind oxygen)

idea of compensation; **R** idea of body getting more oxygen

[max 3]

[Total: 16]

Page 6	Mark Scheme	Syllabus	Paper
	Cambridge International AS/A Level – March 2016	9700	22

### 4 (a) Morbillivirus

aerosol/droplet, infection;

A described, e.g. (from infected person) in, exhaled/airborne, droplets, and inhaled

idea of spread by touching an infected surface and putting fingers into mouth/nose;

R contact without qualification

HIV

sexual intercourse/passed via semen/passed via vaginal fluids/AW; blood transmission; **A** described, e.g. blood transfusion

sharing (contaminated), needles/syringes

accept transmitted in body fluids for one mark if above two points not gained

mother to, foetus/baby, transmission;

A described, e.g. across placenta/during birth/breastfeeding

AVP; e.g. ref. to measles mode of transmission leading to faster spread of disease/ora

[max 4]

(b) antibiotics (only) used against bacteria (and some fungi); I used in malaria

idea that antibiotics act at a cell structure not possessed by virus; e.g. viruses, do not have, a cell wall/a cell surface membrane/ribosomes

suggestion that viruses are, inside host cells/not within reach;

antibiotics act only on, living/growing, cells (viruses do not grow);

antibiotics do not act on, protein coat/capsid/capsomeres/viral envelope;

[max 2]

(c) (i) phospholipid bilayer;

proteins/glycoproteins/named; I cholesterol

[2]

(ii) SLAM acts as a receptor;

haemagglutinin/H/(viral) glycoprotein, binds to/fits into/complementary to, SLAM/receptor;

fusion protein/F/(viral) glycoprotein, causes fusion (of envelope) to cell surface membrane;

 ${f A}$  (viral) envelope fuses with cell surface membrane fusion releases nucleoprotein (and viral polymerase);

[max 3]

rage		Cambridge International AS/A Level – March 2016	9700	22
	(iii)	in context of viral RNA replication of RNA/to make copies of genes/AW;		
		transcription/production of <u>m</u> RNA; detail; e.g. to make viral proteins;		
		AVP; e.g. <i>credit suggestion of,</i> RNA-dependent DNA polymerase transcriptase, to produce viral DNA	e/reverse	[ O]
				[max 2]
(d)	(i)	protein; A polypeptide A glycoprotein		[1]
	(ii)	harvest/collect/AW, splenocytes/B-lymphocytes/B-cells/plasma of fuse with, myeloma cells/cancer cells; A tumour form hybridoma cells;		
		select for (hybridoma) cells secreting antibody against, p24/antiger	ι;	[max 3]
			ļ	[Total: 17]
5 (a)	ribo ade	sphate; set in the set of the set		
		alent bond ;		[max 3]
(b)	(i)	D;		[1]
	(ii)	DACB;		[1]
	(iii)	source;		[1]
(c)	(i)	ref. tRNA role in translation; e.g. amino acid carried by tRNA molecule to ribosome anticodon on tRNA (with specific amino acid) binds to code mRNA tRNAs bring amino acids, adjacent to each other/for pepting		
		idea that mRNA (sequence of) codons dictate which amino acids w added (to polypeptide chain)/AW; ref. correct, sequence of amino acids/primary structure (of, polypeptide);		
		protein);		[max 2]

**Mark Scheme** 

Page 7

Syllabus

Paper

Page 8	Mark Scheme	Syllabus	Paper
	Cambridge International AS/A Level – March 2016	9700	22

(ii) hydrogen/ionic, bonds, break/disrupted; A electrovalent for ionic R if other bonds named

charges at the active site may be affected; changes, shape/(tertiary) structure, of active site;

A changes, <a href="mailto:shape/tertiary structure">shape/tertiary structure</a>, of enzyme

[max 2]

(iii) substrate enters the active site; active site, (partially) flexible/changes shape slightly; ref. provides a better fit/moulds around; allows interaction of R groups (of active site) with substrate;

[max 2]

[Total: 12]

6 (a) trachea/windpipe bronchus/bronchi bronchiole/bronchioles alveolus/alveoli

all correct two marks;;

one mark for:

one structure, incorrect/missing, but others in correct order

or

trachea and alveolus correct but bronchus and bronchiole wrong way round

[2]

(b) emphysema; chronic bronchitis;

[2]

[Total: 4]